Next week, people from around the world will descend on Washington, D.C. for the annual meeting of the American Association for Cancer Research to hear about the latest discoveries in basic science, translational research, clinical trials, and population studies. Under the banner of this year’s theme, Personalizing Cancer Care Through Discovery Science, we are especially looking forward to the many discussions that will be happening around cancer genomics.
Cancer remains one of the great healthcare challenges of our day and continues to claim far too many people at costs in the hundreds of billions of dollars every year. More than 1.6 million Americans will be diagnosed with cancer this year, and some 580,000 are expected to die from some form of the disease – that’s nearly 1,600 people a day.
At RainDance, we are working closely with leading cancer researchers around the world to power projects aimed at elucidating the molecular and biological changes underlying cancer development and progression. By exploiting this growing body of knowledge about cancer biology, we can be more strategic and innovative in the way we tackle cancer, quickening the pace of innovation in preventing, diagnosing, treating, and monitoring these deadly diseases.
Today, we know that because cancer is extremely heterogeneous, it is in fact not a single disease, but likely more than 200 diseases. Further, we are beginning to understand that given this heterogeneity, nearly all cancers are composed of a number of different cancer subtypes, meaning every person’s cancer may be unique.
Understanding these differences is at the heart of what we do at RainDance. Our complete cancer research product portfolio includes solutions for targeted DNA sequencing, ultra-deep sequencing of FFPE and fresh frozen samples, cancer pathway analysis, methylation analysis, and digital PCR. These powerful technologies are enabling researchers to find primary tumor genetic mutations, follow mutations in peripheral locations and track clonal expansion in metastases (see image).
Recent peer-reviewed papers highlighting the capabilities of these innovative picodroplet-based solutions have been published in a number of leading publications. The New England Journal of Medicine and Genome Biology recently published papers that demonstrate our “hotspot” approach for detecting rare genetic mutations linked to cancer. Additional publications include the Journal of Translational Medicine (deep sequencing) as well as PLoS One (methylation analysis) and Genome Research (methylation analysis).
The new RainDance RainDrop™ Digital PCR (dPCR) platform has been highlighted in two Lab on a Chip publications and a recent paper in Chemical Chemistry. These papers describe the platform’s unprecedented multiplexing capabilities, how it was used to detect a single mutated KRAS oncogene in a 200,000-fold background of normal KRAS genes expressed by cell lines, and method for assessing DNA integrity and quantity from paraffin-embedded tissues.
If you will be in attendance at AACR, we’d enjoy the opportunity to talk with you about your projects. We encourage you to come by our booth in the expo hall (#2039) where we’d be happy to answer your questions and share how the power, precision, and simplicity of our picodroplet-based technologies can help you answer your research questions with unparalleled sensitivity and quantification.
The RainDrop Digital PCR System is for Research Use Only. Not for use in diagnostic procedures.